ArticleEuropean journal of nuclear medicine and molecular imaging2026
Addition of quantitative imaging parameters to visual analysis improves the accuracy of PSMA PET/CT for the local staging of primary prostate cancer.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeProstate-specific membrane antigen (PSMA) PET/CT is recognized as the most accurate imaging modality for staging of patients with intermediate and high-risk prostate cancer (PCa). PSMA PET/CT has also shown potential in the local (T) staging of primary PCa. The purpose of this study was to explore the value of quantitative PSMA PET/CT parameters in addition to the standard visual assessment for local T-stage classification in a large single-center retrospective cohort.
methodsSequential intermediate- and high-risk primary PCa patients who underwent staging PSMA PET/CT prior to robot-assisted radical prostatectomy were included. Visual assessment of T-stage (miT-stage) was performed alongside quantitative analysis of PSMA PET/CT parameters, including SUVmax, SUVpeak, tumor volume (PSMA-vol), total lesion PSMA expression (PSMA-TL), and tumor longest capsule contact (LCC). The pathological tumor stage derived from radical prostatectomy specimens served as the reference standard. Univariable and multivariable logistic regression analyses were performed to develop clinical risk models for predicting pT3-stage disease.
resultsA total of 223 evaluable patients with PSMA-positive primary PCa were included. Univariable analyses of individual imaging parameters yielded AUCs of 0.53–0.63 for pT3a, 0.64–0.74 for ≥ pT3b, and 0.59–0.69 for overall ≥ pT3-stage. In multivariable analyses, LCC was the sole independent predictor for pT3a stage; miT-stage, LCC, and PSMA-vol were independent predictors for ≥ pT3b-stage; and LCC together with PSMA-vol were independent predictors for overall ≥ pT3-stage. Clinical risk models incorporating these predictors achieved AUCs of 0.62 for pT3a, 0.79 for ≥ pT3b, and 0.70 for ≥ pT3-stage.
conclusionQuantitative parameters derived from PSMA PET/CT scans provide additional diagnostic accuracy for detecting extraprostatic tumor extension, particularly for ≥ pT3b-stage disease, outperforming visual assessment (miT-stage) alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.